USPSTF Review: T2DM Screening Doesn't Cut Mortality

Share this content:
USPSTF Review: T2DM Screening Doesn't Cut Mortality
USPSTF Review: T2DM Screening Doesn't Cut Mortality

(HealthDay News) -- Type 2 diabetes screening is not associated with improved mortality rates after 10 years of follow-up, according to a U.S. Preventive Services Task Force (USPSTF) review published online April 14 in the Annals of Internal Medicine.

Shelley Selph, M.D., M.P.H., from Pacific Northwest Evidence-Based Practice Center and Oregon Health & Science University in Portland, and colleagues conducted a systematic literature review to update the 2008 USPSTF review on diabetes screening in adults.

The researchers found that screening for diabetes correlated with no 10-year mortality benefit versus no screening in two trials. Based on 16 trials, there was consistent evidence that treatment of impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) correlated with delayed progression to diabetes. Most trials of IFG or IGT treatment found no effects on all-cause or cardiovascular mortality, but in one trial, lifestyle modification correlated with reduced risk for both outcomes after 23 years. In one trial there was no effect of an intensive multifactorial intervention on risk for all-cause or cardiovascular mortality versus standard control for screen-detected diabetes. Nine systematic reviews showed that intensive glucose control did not reduce the risk for all-cause or cardiovascular mortality in diabetes that was not specifically screen-detected, and intensive blood pressure control results were inconsistent.

"More evidence is needed to determine the effectiveness of treatments for screen-detected diabetes," the authors write.

Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »